UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$191M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$157M |
| 3 |
Pfizer
PFE
|
+$139M |
| 4 |
3M
MMM
|
+$131M |
| 5 |
Meta Platforms (Facebook)
META
|
+$106M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALTR
Altera Corp
ALTR
|
+$288M |
| 2 |
Intercontinental Exchange
ICE
|
+$247M |
| 3 |
RKT
ROCK-TENN COMPANY CL-A
RKT
|
+$142M |
| 4 |
Yelp
YELP
|
+$140M |
| 5 |
Salesforce
CRM
|
+$135M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.28% |
| 2 | Financials | 14.69% |
| 3 | Technology | 14.25% |
| 4 | Consumer Discretionary | 9.55% |
| 5 | Industrials | 8.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Nike
NKE
$64.1B
| $663M | 0.63% |
12,277,488
+84,780
| +0.7% | +$4.34M |
|
27
Cisco
CSCO
$443B
| $650M | 0.62% |
23,685,000
+126,163
| +0.5% | +$3.62M |
|
28
Starbucks
SBUX
$119B
| $643M | 0.62% |
11,985,370
-159,722
| -1% | -$8.1M |
|
29
UnitedHealth
UNH
$382B
| $641M | 0.61% |
5,253,062
-2,328
| -0% | -$275K |
|
30
Merck
MRK
$322B
| $632M | 0.61% |
11,636,548
+409,998
| +4% | +$23M |
|
31
Amgen
AMGN
$209B
| $629M | 0.6% |
4,095,485
+30,418
| +0.7% | +$4.87M |
|
32
IBM
IBM
$213B
| $596M | 0.57% |
3,832,493
-177,167
| -4% | -$28.5M |
|
33
Mastercard
MA
$498B
| $587M | 0.56% |
6,274,720
+449,012
| +8% | +$41.2M |
|
34
Verizon
VZ
$197B
| $586M | 0.56% |
12,568,267
+68,224
| +0.5% | +$3.34M |
|
35
Intel
INTC
$413B
| $576M | 0.55% |
18,946,202
+250,544
| +1% | +$8.1M |
|
36
Coca-Cola
KO
$383B
| $547M | 0.52% |
13,944,775
+326,608
| +2% | +$13.3M |
|
37
AbbVie
ABBV
$465B
| $529M | 0.51% |
7,874,790
-1,755,164
| -18% | -$115M |
|
38
SLB Ltd
SLB
$72.7B
| $511M | 0.49% |
5,930,293
+46,270
| +0.8% | +$4.18M |
|
39
CVS Health
CVS
$135B
| $511M | 0.49% |
4,872,649
+431,448
| +10% | +$44.1M |
|
40
TJX Companies
TJX
$179B
| $501M | 0.48% |
15,151,720
+1,182,538
| +8% | +$39.3M |
|
|
ESRX
41
DELISTED
Express Scripts Holding Company
ESRX
| $497M | 0.48% |
5,593,084
-6,928
| -0.1% | -$605K |
|
42
Oracle
ORCL
$339B
| $493M | 0.47% |
12,244,971
-22,395
| -0.2% | -$971K |
|
43
Philip Morris
PM
$309B
| $476M | 0.46% |
5,937,343
+86,663
| +1% | +$7.13M |
|
44
Thermo Fisher Scientific
TMO
$214B
| $476M | 0.46% |
3,667,295
+320,532
| +10% | +$41.8M |
|
45
Biogen
BIIB
$30.9B
| $471M | 0.45% |
1,166,412
-5,067
| -0.4% | -$2.03M |
|
|
46
3M
MMM
$91.8B
| $465M | 0.45% |
3,606,554
+976,390
| +37% | +$131M |
|
47
Booking.com
BKNG
$156B
| $454M | 0.43% |
9,853,850
-92,350
| -0.9% | -$4.41M |
|
48
American International
AIG
$42.5B
| $437M | 0.42% |
7,061,448
-543,740
| -7% | -$32.1M |
|
49
US Bancorp
USB
$97.9B
| $431M | 0.41% |
9,933,858
+2,921
| +0% | +$128K |
|
50
Qualcomm
QCOM
$164B
| $418M | 0.4% |
6,666,227
-174,595
| -3% | -$11.9M |
|
Similar funds
UBS AM's Q2 2015 Portfolio in Review
As of Q2 2015, UBS AM held 2,771 positions worth $104B, up 0.68% from $104B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
UBS AM's Q2 2015 filing shows 148 new, 1,779 increased, 566 reduced and 77 closed positions. Its largest new stake was Viatris: 1,260,214 shares worth $85.5M. The largest sale was Altera Corp, an estimated $288M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 17% a quarter earlier, followed by Financials and Technology.
- UBS AM's largest Q2 2015 buy was Viatris: 1,260,214 shares worth $85.5M.
- UBS AM added most to Allergan plc in Q2 2015, an estimated $191M increase.
- UBS AM's biggest Q2 2015 reduction was Altera Corp, cutting an estimated $288M.
- UBS AM fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $78.3M.
- UBS AM's ten largest holdings make up 14% of its $104B portfolio in Q2 2015.
- UBS AM opened 148 new positions and closed 77 in Q2 2015.
- UBS AM's portfolio value rose 0.68% quarter-over-quarter to $104B.
Based on UBS AM's 13F filing for Q2 2015, filed 12 Aug 2015.